PROGNOSTIC SIGNIFICANCE OF CD123 (IL3RA) EXPRESSION IN PATIENTS WITH ACUTE LEUKEMIAS
Keywords:
CD123, interleukin-3, acute lymphoblastic leukemia, acute myeloid leukemiaAbstract
This study evaluated the clinical and prognostic significance of CD123 (IL3RA) expression in patients with acute leukemia. A total of 116 patients were included in this single-center observational study. CD123 expression in bone marrow blast cells was assessed by multiparameter flow cytometry and quantified as the percentage of CD123-positive cells. CD123 expression was detected in 79.3% of patients, with high expression (≥50%) observed in 68.1%. The highest levels were found in myeloid, myelomonocytic, and monoblastic variants.
High CD123 expression was associated with increased bone marrow blast infiltration, aggressive disease course, primary resistance to therapy, and early relapse. A prognostic risk score incorporating CD123 expression, blast percentage, and leukemia subtype was developed and demonstrated acceptable predictive performance (AUC ≈0.74).
The findings support the inclusion of CD123 in routine immunophenotyping panels and highlight its role as a prognostic biomarker for risk stratification and individualized therapeutic decision-making in acute leukemia.
References
Alvarez S, Su Y, Harrold J va boshqalar.Bispesifik antikorlar va CAR-T hujayralari yordamida o'tkir leykemiyada CD123 ni nishonga olish. Leykemiya 2022;36(3):684–696.(m.Ing)
Jen WY va boshqalar.Tagraxofusp: birinchi darajali CD123-ni nishonga oluvchi vosita.
Am. Saraton Jamiyati sharhi2024. Klinik ma'lumotlar tahlili va CD123 asosidagi maqsadli terapiyani ishlab chiqish, shu jumladan tasdiqlangan tagraksofusp preparati va uning boshqa agentlar bilan potentsial kombinatsiyalari.( m.Ing)
Pelosi E., Kastelli G., Testa U.CD123 o'tkir miyeloid leykemiya va blastik plazmatsitoid dendritik neoplazma uchun terapevtik maqsad sifatida.
Xalqaro J. Mol. Sci.2023;24(3):2718. CD123 ekspressiyasi bo'yicha mavjud ma'lumotlarni va AML/BPDCN da maqsadli terapiya potentsialini, jumladan, antikorlarga asoslangan terapiya va CAR-T yondashuvlarini ko'rib chiqish.(m.Russ)
Stein AS va boshqalar.O'tkir leykemiyada CD123-ni nishonga oluvchi agentlarning (bispesifik antikorlar, CAR yondashuvlari) insonda birinchi marta o'tkazilgan tadqiqotlari. Qaytalanuvchi/refrakter AML/B-ALL bilan og'rigan bemorlarda bispesifik antikorlarning xavfsiz dozasi va boshqa CD123-ni nishonga oluvchi terapiyalarning pilot tadqiqotlari.(m.Russ)
O'tkir miyeloid leykemiya uchun immunoterapiya: Hozirgi strategiyalar.
Karger sharhi2023. CD123-ni nishonga oluvchi vositalar, ularning cheklovlari va istiqbollariga urg'u bergan holda AMLda mavjud immunoterapevtik yondashuvlarni ko'rib chiqish(m.Russ).
O'tkir leykemiyada IL3RA kanserogenezining tizimli pan-saraton tahlili.
CD123 (IL3RA) ning o'tkir leykemiyalarda biomarker sifatida 2025-yilgi nashr tahlili, shu jumladan AML va B-ALLda ekspressiyaning klinik natijalar bilan bog'liqligi va prognostik ahamiyati(m.Russ)
Pagano L, Valentini CG, Pulsoni A va boshqalar.Blastik plazmatsitoid dendritik hujayrali neoplazma: diagnostika mezonlari va terapevtik yondashuvlar. Hematologica. 2021;106(2):321–330.(m.Ing)
Tettamanti S, Marin V, Pizzitola I va boshqalar.Sitokinlar tomonidan qo'zg'atilgan o'tkir miyeloid leykemiyani yangi anti-CD123 ximerik antigen retseptorlari bilan yo'naltirilgan qotil hujayralar tomonidan nishonga olish. Clin Cancer Res. 2022;28(5):1045–1056.(m,Ing)
Jen WY, Nichols J, Wang ES.Tagraxofusp: gematologik xavfli o'smalarni davolash uchun birinchi darajali CD123-ni maqsadli davolash usuli. CA Cancer J Clin. 2024;74(1):45–58.(m.ing)
Stein AS, Jongen-Lavrensic M, Garciaz S va boshqalar.O'tkir leykemiya uchun CD123 asosidagi maqsadli terapiyaning hozirgi holati va kelajakdagi salohiyati. Leykemiya 2024;38(2):239–252.(m.Ing)
Zhang L, Li Y, Wang J va boshqalar.O'tkir leykemiyada IL3RA (CD123) ekspressiyasining prognostik qiymati: tizimli tahlil. Ann Hematol. 2025;104(1):15–27.(m.Ing)
